ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq

ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ:BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.

ChemDiv's ongoing collaboration includes accelerated CMC research, AI-enabled pharmacology, computational modeling, and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023–2024. ChemDiv's medicinal chemistry, in vitro and in vivo biology, and pharmacology services were instrumental in differentiating:

MEN PPI inhibitors – first-in-class candidates that enhance islet cell proliferation and demonstrate therapeutic potential in T2D.

TYK2 inhibitors – best-in-class compounds that reduce pro-inflammatory cytokine signaling, preserving islet cell function to prevent and treat T1D.

Together with Clywedog's other partners, ChemDiv enabled the rapid progression of both programs from discovery to clinic in less than three years.

Barinthus–Clywedog Combination

Barinthus Biotherapeutics and Clywedog Therapeutics have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. The combined company brings together leading expertise in immunology and metabolic disease with three clinical-stage assets and multiple near-term data milestones. Leadership will include executives from both organizations, with transaction closing targeted for the first half of 2026.